Encouragingly, our current study was the largest trial which demonstrated that patients with hematologic malignancies receiving G-CSF-primed BM with PBSCs harvests in HLA3/6-matched setting had similar outcomes regardless of relapse, TRM and survival, when compared with patients only receiving G-CSF-mobilized PBSCs in HLA4/6-matched HSCT. This evidence concerns the gene CSF3 and hematologic disorder.